Tag: ImmunoACT
Cipla partners ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell...
Under this partnership, Cipla will commercialize talicabtagene autoleucel, India’s first indigenously developed CAR-T cell therapy, in the Republic of South Africa, Algeria, and Morocco
ICMR signs MOAs with industry & academic partners to advance first-in-human...
The partnership marks a pivotal step towards establishing India’s self-sufficiency in clinical development and advancing indigenous pharmaceutical agents
Fortis Healthcare launches advanced ‘Fortis Institute of Blood Disorders’
This initiative is supported by a commercial collaboration with ImmunoACT, an IIT-Bombay spin-off and pioneer in India’s first fully indigenous and commercially approved gene-modified cell therapy